<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721314</url>
  </required_header>
  <id_info>
    <org_study_id>00000090</org_study_id>
    <nct_id>NCT04721314</nct_id>
  </id_info>
  <brief_title>Personalized Pacing: A New Paradigm for Patients With Diastolic Dysfunction or Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>myPACE</acronym>
  <official_title>Personalized Pacing: A New Paradigm for Patients With Diastolic Dysfunction or Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent exploratory studies suggest that pacemaker patients with diastolic dysfunction (DD) or&#xD;
      heart failure with preserved ejection fraction (HFpEF) may benefit from a higher backup heart&#xD;
      rate (HR) setting than the factory setting of 60 beats per minute (bpm). In this prospective&#xD;
      double-blinded randomized controlled study, pacemaker patients with DD or overt HFpEF and&#xD;
      either 1) intrinsic ventricular conduction or 2) conduction system or biventricular pacing&#xD;
      will be enrolled and randomized to either a personalized lower HR setting (myPACE group,&#xD;
      based on a height-based HR algorithm) or to the standard 60bpm backup setting (control group)&#xD;
      for 1 year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients are randomized to either a personalized pacemaker lower heart rate setting based on a resting heart rate algorithm or to the conventional pacemaker lower rate setting of 60bpm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>All investigators are blinded to patient randomization. To assess subject blinding, participants are asked at 1 month and 12 month follow up if they believed that their pacemaker lower rate was changed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Minnesota Living with Heart Failure Questionnaire Score</measure>
    <time_frame>Baseline, 1 month, and 12 months</time_frame>
    <description>Change in score from baseline (at enrollment) to 1 month and 12 months after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NTproBNP</measure>
    <time_frame>Baseline, 1 month</time_frame>
    <description>Change in NTproBNP level from baseline to 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization or invasive outpatient intervention for heart failure</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Arrhythmia Burden</measure>
    <time_frame>At 12 months</time_frame>
    <description>On pacemaker reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loop diuretic initiation or up-titration</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-arrhythmic initiation or up-titration</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacemaker-detected activity levels</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalizations or invasive outpatient intervention for heart failure exacerbation, atrial tachyarrhythmias, cerebrovascular accident, or myocardial infarction</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Pacemaker</condition>
  <condition>Diastolic Dysfunction</condition>
  <condition>Diastolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Lower rate set to a higher, personalized backup heart rate (myPACE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this group will have their pacemaker lower heart rate setting programmed to a personalized lower rate based on a resting heart rate algorithm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower rate left at 60 beats-per-minute</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will have their pacemaker lower heart rate setting left at or programmed to the conventional pacemaker lower rate setting of 60bpm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adjustment of lower rate limit</intervention_name>
    <description>Patients with preserved ejection fraction (EF &gt;50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.</description>
    <arm_group_label>Lower rate set to a higher, personalized backup heart rate (myPACE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Maintenance of lower rate limit</intervention_name>
    <description>Lower rate limit will be maintained at 60 beats-per-minute</description>
    <arm_group_label>Lower rate left at 60 beats-per-minute</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Implanted pacemaker with either 1) intrinsic ventricular conduction or 2) conduction&#xD;
             system or biventricular pacing or 3) RV pacing &lt;2% and paced QRS duration &lt;150ms&#xD;
&#xD;
          -  Clinical evidence of heart failure with preserved ejection fraction or diastolic&#xD;
             dysfunction, based on:&#xD;
&#xD;
               -  dyspnea with exertion&#xD;
&#xD;
               -  or NYHA Class ≥ II heart failure&#xD;
&#xD;
               -  or pulmonary edema on prior chest imaging or documented on exam&#xD;
&#xD;
               -  or is taking loop diuretics for heart failure&#xD;
&#xD;
               -  or had NTproBNP &gt;400 ng/ml in the last 24 months&#xD;
&#xD;
               -  or a heart failure hospitalization in the last 2 years&#xD;
&#xD;
               -  or has diastolic dysfunction on echo&#xD;
&#xD;
               -  or has left ventricular hypertrophy on echo&#xD;
&#xD;
               -  or has left atrial (LA) dilation (LA volume/BSA index &gt;28ml/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50%&#xD;
&#xD;
          -  Life expectancy &lt; 12 months&#xD;
&#xD;
          -  Symptomatic pulmonary disease on home oxygen&#xD;
&#xD;
          -  Uncontrolled hypertension as defined by blood pressure &gt;160/100 mmHg on two checks ≥15&#xD;
             minutes apart&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  More than moderate valvular disease&#xD;
&#xD;
          -  Aortic valve replacement &lt; 1 year&#xD;
&#xD;
          -  Angina pectoris&#xD;
&#xD;
          -  Creatinine &gt; 2&#xD;
&#xD;
          -  Hemoglobin &lt; 8 g/dL&#xD;
&#xD;
          -  Participation in another clinical trial or registry study&#xD;
&#xD;
          -  Inability to follow up for regularly scheduled pacemaker appointments or to follow up&#xD;
             for this study&#xD;
&#xD;
          -  Pregnant patients or patients of childbearing age without reliable contraceptive agent&#xD;
             (intra-uterine device, birth control implant, compliance with contraception injections&#xD;
             or contraception pills) for the duration of study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Meyer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 16, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Margaret Infeld</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Heart failure with preserved ejection fraction</keyword>
  <keyword>Diastolic dysfunction</keyword>
  <keyword>Resting heart rate</keyword>
  <keyword>Personalized</keyword>
  <keyword>Lower rate setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

